Table 1: Main patients’ characteristics.

AgeGenderDiseaseDisease statusHLA matchOverall number of infused donor cells (×107/kg)Number of donor CD34+ cells (×105/kg)Time to PMN recovery (≥0.5 × 109/L), daysTime to PLT recovery (≥20 × 109/L), daysPLT count at day 100 (×109/kg)

66MnHLRefractory4/62.130.683248130
36FAML2 CR4/64.152.32223028
25MCMLRefractory4/62.290.412123165
44MAML2 CR4/64.071.262738101
49FAML1 CR (HR)4/63.402.202333122
48MAML/HDSecondary after HD4/62.852.702745
47MAML1 CR (HR)4/62.001.691838111
42MALLRefractory4/64.400.862713
34MHDRefractory4/63.491.962442124
37MALLRefractory4/63.121.041434175
22FCMLDisease relapse4/65.203.381418/
43FHDRefractory4/63.280.802332148
33MALLRefractory4/63.451.14232677
49FAML1 CR (HR)4/63.872.672235155
50MAMLRefractory4/62.740.532944100
58MnHLRefractory4/62.581.582438127
46FCMLDisease relapse4/61.971.602439/
38MAML2 CR4/62.191.001937212
36MAMLRefractory4/62.461.001929
56MCMLRefractory4/62.901.671934118
58MPMFRefractory4/63.361.71243651

ALL: acute lymphatic leukemia; AML: acute myeloid leukemia; CML: chronic myeloid leukemia; HD: Hodgkin’s disease; nHL: non-Hodgkin’s lymphoma; PMF: primary myelofibrosis; 1 CR: first complete remission; 2 CR: second complete remission; HR: high risk; PMN: polymorphonucleated cells; PLT: platelets; Patient died.